BioXcel Therapeutics (BTAI)
(Delayed Data from NSDQ)
$0.66 USD
+0.02 (2.98%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $0.67 +0.01 (2.10%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.66 USD
+0.02 (2.98%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $0.67 +0.01 (2.10%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth C Momentum F VGM
Zacks News
BioXcel Therapeutics (BTAI) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
BioXcel Therapeutics (BTAI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of 72.37% and 38%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
BioXcel Surges on Fast Track Designation to Agitation Drug
by Zacks Equity Research
BioXcel (BTAI) soars after the FDA granted Fast Track designation to its lead candidate, BXCL501.